WHO Strengthens Biosimilar Regulatory Review for Better Patient Access
The World Health Organization (WHO) is enhancing the regulatory review process for biosimilars to improve patient access to affordable, quality, safe, and effective treatments. This move aims to ensure that more patients can benefit from biosimilar medicines, which are alternatives to original biologic drugs, thereby supporting healthcare systems worldwide.
World Health Organization (WHO)·5h ago




